All In Biotech

Drug Trial Radar · NCT02646566

Study of APD421 as PONV Treatment (Prior Prophylaxis)

Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had Prior Prophylaxis

Last checked: Nov 20, 2026Latest source record: Jan 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 705 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

705

Actual

Start

Mar 2016

Primary completion

Jan 2017

Study completion Jan 2017

Sponsor

Lead sponsor
Acacia Pharma LtdIndustry
Sponsor type
Industry
First posted
Jan 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have had prior PONV prophylaxis.

Conditions

  • Postoperative Nausea and Vomiting

Interventions

  • APD421Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Complete Response (Success of Initial PONV Treatment)Time frame: 0-24 hours after administration of study medication

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Jackson Memorial Hospital

    Miami, Florida

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • Ohio State University

    Columbus, Ohio

  • CHU de Hautepierre

    Strasbourg, France

  • HELIOS Klinikum Aue

    Aue, Germany

  • Universität Heidelberg

    Heidelberg, Germany

  • Philipps University

    Marburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.